Novartis is one of the world’s leading pharmaceutical companies.
Novartis has emerged from a multi-year strategic transformation as one of the industry’s most focused and highest-performing pure-play innovative medicine companies. Following the 2023 spin-off of Sandoz, Novartis operates exclusively in innovative medicines, generating approximately $55 billion in 2025 revenues with an 11% growth rate. The radioligand therapy platform — Pluvicto and Lutathera — is Novartis’s most strategically distinctive asset. Entresto at approximately $8 billion for heart failure and Leqvio the first-in-class siRNA therapy anchor the cardiovascular franchise.
This report provides comprehensive strategic intelligence on Novartis — covering strategic directions, financial performance, SWOT analysis, technological know-how, latest products and services, M&A, marketing tactics, and organization and management.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and key platforms
• Latest products, programs, and innovation pipeline
• M&A activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Novartis — Key Financial Metrics 2023-2025
Table 2. Novartis — Revenue by Therapeutic Area 2023-2025
Table 3. Novartis — Revenue by Geography 2023-2025
Table 4. Novartis — R&D Investment 2023-2025
Table 5. Novartis — SWOT Analysis
Table 6. Novartis — Key Technology Platforms
Table 7. Novartis — Top Products by Revenue 2025
Table 8. Novartis — Late-Stage Pipeline 2025
Table 9. Novartis — M&A Activity 2023-2025
Table 10. Novartis — Key Management
Table 11. Novartis — Strategic Priorities 2025-2030
